{"id":34632,"date":"2025-06-11T00:48:14","date_gmt":"2025-06-10T22:48:14","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/06\/11\/rgs1-is-an-effective-t-cell-marker-of-acute-myeloid-leukemia-remission-after-hematopoietic-stem-cell-transplantation\/"},"modified":"2025-06-11T00:48:14","modified_gmt":"2025-06-10T22:48:14","slug":"rgs1-is-an-effective-t-cell-marker-of-acute-myeloid-leukemia-remission-after-hematopoietic-stem-cell-transplantation","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/06\/11\/rgs1-is-an-effective-t-cell-marker-of-acute-myeloid-leukemia-remission-after-hematopoietic-stem-cell-transplantation\/","title":{"rendered":"RGS1 is an effective T-cell marker of acute myeloid leukemia remission after hematopoietic stem cell transplantation"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2025 Jun 10:vkaf096. doi: 10.1093\/jimmun\/vkaf096. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Disease relapse is a major cause of death in acute myeloid leukemia (AML) patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The characterization of novel functional T-cell subtypes is critical for predicting clinical responses as well as developing strategies for immunotherapy in leukemia. We used single-cell RNA-sequencing to resolve the T cells&#8217; profiles of AML patients who had a relapse (RL) or reached complete remission (CR) after HSCT and addressed the characteristics of T cells at molecular level under HSCT scenario. Ten T-cell subtypes were identified in these RL and CR patient groups, of which mature T cells subtypes, such as CD8+ T effector memory (TEM), CD8+ T effector (TEFF), CD4+ TEM, and CD4+ TEFF cells, tended to be more abundant in the CR group, while na\u00efve CD8, na\u00efve CD4, and exhausted CD8+ T cells occupied larger proportions in the RL group. Of note, we identified that RGS1 (regulator of G-protein signaling 1) highly expressing CD8+ TEFFs tended to enrich in the CR group. Higher levels of RGS1 in CD8+ TEFF, CD8+ T, and CD3+ T cells were significantly associated with remission after HSCT in AML patients, which could also predict clinical outcomes after allo-HSCT. And the elevation of RGS1 levels in CD8+ T cells increased cytotoxic factor production, possibly by activating the NF-\u03baB signaling pathway. These findings provide valuable insights into T-cell characteristics under allo-HSCT and identify RGS1 as a new marker potentially predicting clinical responses for AML after allo-HSCT.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40493523\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20250610184813&amp;v=2.18.0.post9+e462414\">40493523<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkaf096\">10.1093\/jimmun\/vkaf096<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2025 Jun 10:vkaf096. doi: 10.1093\/jimmun\/vkaf096. Online ahead of print. ABSTRACT Disease relapse is a major cause of death in acute myeloid leukemia (AML) patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The characterization of novel functional T-cell subtypes is critical for predicting clinical responses as well as developing strategies for immunotherapy in leukemia. &#8230; <a title=\"RGS1 is an effective T-cell marker of acute myeloid leukemia remission after hematopoietic stem cell transplantation\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/06\/11\/rgs1-is-an-effective-t-cell-marker-of-acute-myeloid-leukemia-remission-after-hematopoietic-stem-cell-transplantation\/\" aria-label=\"Read more about RGS1 is an effective T-cell marker of acute myeloid leukemia remission after hematopoietic stem cell transplantation\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-34632","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/34632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=34632"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/34632\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=34632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=34632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=34632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}